Highlights Novo Nordisk A/S

Stocks

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-07-10 am EDT			5-day change	1st Jan Change
322.25 ^DKK	+0.66%		-1.42%	-0.92%

Jul. 11	Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig In Phase 3 Hemophilia a Frontier Extension Study	CI
Jul. 10	Nordic stocks in North America: Astra Zeneca rose 0.6%	FW

Highlights

Jul. 11	Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig In Phase 3 Hemophilia a Frontier Extension Study	CI
Jul. 03	UK Regulator Conditionally Approves Novo Nordisk's Wegovy to Treat Form of Liver Disease	MT
Jul. 03	UK Medicines Regulator Approves Novo Nordisk's Wegovy to Treat Form of Liver Disease	MT
Jul. 01	Novo Nordisk Announces Wegovy Now Accessible to Eligible Medicare Beneficiaries Living with Obesity Through Medicare GLP-1 Bridge	CI
Jun. 25	Hims' obesity drug business may get boost as employers drop coverage	RE
Jun. 17	Berenberg Ups Novo Nordisk Price Target on Expected Wegovy Volume Growth; Buy Rating Kept	MT
Jun. 16	US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugs	RE
Jun. 12	MedPal AI Says New Health Clinic Could Benefit from UK Approval of Oral Weight Loss Drug	MT
Jun. 12	Novo Nordisk Reports IT Security Breach
Jun. 11	UK Regulator Approves Novo Nordisk's Weight-loss Pill	MT
Jun. 11	Novo Nordisk Wins UK Approval for Wegovy Weight-Loss Pill	MT
Jun. 11	Novo Nordisk says security incident has access to limited internal IT systems	RE
Jun. 11	Novo Nordisk Receives UK Approval For Wegovy Pill For Weight Management	CI
Jun. 10	Novo Nordisk Sues South African Manufacturer Over Semaglutide Copies
Jun. 10	Novo Nordisk faces off in court with South African weight-loss drug compounder	RE
Jun. 08	Health Care Ticks Down Amid Deal Activity - Health Care Roundup	DJ
Jun. 07	Novo Nordisk Launches Wegovy Pill in the United Arab Emirates	CI
Jun. 06	Novo Nordisk Reports Real-World Evidence Comparing Semaglutide 2 Mg Dose Escalation Versus Switch to Tirzepatide in Adults with Type 2 Diabetes	CI
Jun. 06	Novo Nordisk Presents Positive Phase 2 Results for Investigational Zenagamtide in Adults with Type 2 Diabetes	CI
Jun. 04	Novo Holdings commits 500 million euros in new European tech growth fund	RE
Jun. 03	Novo Nordisk Expands Access to Wegovy Pill in the United Arab Emirates	CI
Jun. 02	Novo Nordisk Partners With Metabolic for Early Access to Oral Wegovy in UAE	MT
May. 26	Synthetic Version of Novo Nordisk's Ozempic Gets Approval in Brazil	MT
May. 26	Generic Version of Novo Nordisk's Ozempic Gets Approval in Brazil	MT
May. 26	Novo Nordisk Presents Results from the POSEIDON Real-World Evidence Study on Cardiovascular Inflammation in People with Cardiovascular Disease	CI